Evidence map›Paper›PMID 27059391›Full record

ReviewBrain research2016

There has been an awakening: Emerging mechanisms of C9orf72 mutations in FTD/ALS.

Aaron D Gitler, Hitomi Tsuiji

Open access · hybridAbstract readReview
In one paragraph

Review in Brain research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 1 pooled it
14.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

108 citing papers in PubMed, 1 synthesis or guideline pooled it, 159 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Intrathecal (GActa neuropathologica communications · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Intrathecal (GbioRxiv : the preprint server for biology · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. DNA methylation as a contributor to dysregulation ofbioRxiv : the preprint server for biology · 2025
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Hybrid PET/MRI in Neurodegenerative Disorders.Advances in clinical radiology · 2024
    Article
  17. Article
  18. Review
  19. Review
  20. Article

48 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Aaron D GitlerDepartment of Genetics, Stanford University School of Medicine, 300 Pasteur Drive, M322 Alway Building, Stanford, CA 94305, USA. Electronic address: agitler@stanford.edu.
Hitomi TsuijiDepartment of Biomedical Science, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabedori, Mizuhoku, Nagoya, Aichi 467-8603, Japan. Electronic address: hitomitsuiji@phar.nagoya-cu.ac.jp.
Nagoya City University · JPStanford University · US

Funding

Molecular Basis of TDP-43 Proteinopathies: Disease Models and MechanismsR01NS065317 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI GITLER, AARON D. · 2009 to 2016
$2.7M
Ataxin-2 as a genetic risk factor for ALS: New insights into neurodegenerationR01NS073660 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI BONINI, NANCY M, GITLER, AARON D. · 2011 to 2015
$1.7M
Defining the mechanisms of dipeptide repeat protein toxicity in C9orf72 ALS/FTDR01NS093865 · NINDS · STANFORD UNIVERSITY · PI GITLER, AARON D., PETRUCELLI, LEONARD · 2015 to 2016
$583k
NINDS NIH HHS R01 NS065317NINDS NIH HHS R01 NS073660NINDS NIH HHS R01 NS093865
6 · The paper itself

Abstract

The discovery of C9orf72 mutations as the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) has awakened a surge of interest in deciphering how mutations in this mysterious gene cause disease and what can be done to stop it. C9orf72 harbors a hexanucleotide repeat, GGGGCC, in a non-coding region of the gene and a massive expansion of this repeat causes ALS, FTD, or both (FTD/ALS). Many questions lie ahead. What does this gene normally do? What is the consequence of an enormous GGGGCC repeat expansion on that gene's function? Could that hexanucleotide repeat expansion have additional pathological actions unrelated to C9orf72 function? There has been tremendous progress on all fronts in the quest to define how C9orf72 mutations cause disease. Many new experimental models have been constructed and unleashed in powerful genetic screens. Studies in mouse and human patient samples, including iPS-derived neurons, have provided unprecedented insights into pathogenic mechanisms. Three major hypotheses have emerged and are still being hotly debated in the field. These include (1) loss of function owing to decrease in the abundance of C9orf72 protein and its ability to carryout its still unknown cellular role; (2) RNA toxicity from bidirectionally transcribed sense (GGGGCC) and antisense (GGCCCC) transcripts that accumulate in RNA foci and might sequester critical RNA-binding proteins; (3) proteotoxicity from dipeptide repeat proteins produced by an unconventional form of translation from the expanded nucleotide repeats. Here we review the evidence in favor and against each of these three hypotheses. We also suggest additional experiments and considerations that we propose will help clarify which mechanism(s) are most important for driving disease and therefore most critical for considering during the development of therapeutic interventions. This article is part of a Special Issue entitled SI:RNA Metabolism in Disease.

Indexed as

MutationAmyotrophic Lateral SclerosisAnimalsC9orf72 ProteinDipeptidesDNA Repeat ExpansionFrontotemporal DementiaHumansMiceProteinsRNAC9orf72 ProteinC9orf72 protein, humanDipeptidesProteinsRNAALS, FTDC9orf72Dipeptide repeat proteinRNA

Identifiers

PMID27059391
PMCPMC5003651
OpenAlexW2334207469

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.